Azitra Inc Secures $1.5M in Private Placement

TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off An announcement from Azitra Inc ( (AZTR) ) is now available. On November 24, 2025, Azitra, Inc. entered into a securities purchase agreement with an institutional investor, resulting in a private placement offering of approximately $1.5 million. The offering involved shares of common stock and warrants, with the proceeds intended for general corporate purposes. The agreement includes restrictions on issuing additional shares for 60 days and grants the investor participation rights in future financings. The placement was facilitated by Maxim Group LLC, and the company is required to file a registration statement for the resale of the securities. The most recent analyst rating on (AZTR) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page. Spark’s Take on AZTR Stock According to Spark, TipRanks’ AI Analyst, AZTR is a Underperform. Azitra Inc’s overall stock score is primarily impacted by its financial performance, characterized by significant revenue growth but overshadowed by high losses and negative cash flows. Technical analysis indicates a bearish trend with oversold conditions, while valuation metrics are unattractive due to negative earnings. The lack of earnings call data and corporate events further limits positive influences on the score. To see Spark’s full report on AZTR stock, click here. More about Azitra Inc Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Its lead program, ATR-12, targets Netherton syndrome, a severe skin disease, while ATR-04 addresses skin toxicity associated with EGFR inhibitors. Azitra utilizes a proprietary platform of engineered proteins and live biotherapeutic products, enhanced by AI and machine learning, to develop its treatments. Average Trading Volume: 4,324,893 Technical Sentiment Signal: Sell Current Market Cap: $3.3M Find detailed analytics on AZTR stock on TipRanks’ Stock Analysis page.